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Abstract
Macrocycles were designed to antagonize the protein–protein interaction p53-MDM2 based on the three-finger pharmacophore
F19W23L25. The synthesis was accomplished by a rapid, one-pot synthesis of indole-based macrocycles based on Ugi macrocycliza-
tion. The reaction of 12 different α,ω-amino acids and different indole-3-carboxaldehyde derivatives afforded a unique library of
macrocycles otherwise difficult to access. Screening of the library for p53-MDM2 inhibition by fluorescence polarization and
1H,15N HSQC NMR measurements confirm MDM2 binding.
Introduction
Macrocycles are the chemical entities that are consisting of a
12-membered or even bigger ring. It is estimated that 3% of the
known natural products consists of a macrocyclic ring [1-5].
Compared to macrocycles in synthetic molecules, the aforemen-
tioned occurrence is still over proportional; for that reason,
these compounds have delighted scientists worldwide due to
their special physicochemical properties, their roles in biologi-
cal systems and the associated synthetic challenges [6,7]. How-
ever, only few synthetic methods allow for the convergent and
fast access to a large macrocyclic chemical space [8-10]; most
of the times their synthesis is complex, multistep and sequen-
tial [11,12]. For this reason a great effort is ongoing to utilize
multicomponent reactions for the synthesis of macrocycles
[8,13-25].
The p53 protein is a well-studied protein which has a leading
role in protecting our organism from cancer. It was found that
most of the human cancers have either mutated the p53 itself or
the p53 pathway is inhibited. The latter group of tumors retains
the wild type p53 (wt-p53) but its pathway is inactivated by
Beilstein J. Org. Chem. 2019, 15, 513–520.
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Scheme 1: MCR approach to indole-based macrocycles; a more effective strategy is proposed in this work, based on α,ω-amino acids and an Ugi
macrocyclization.
Scheme 2: Reaction of unprotected diamines 3 with cyclic anhydrides 4 at rt affording α,ω-amino acids 5 in quantitative yields.
negative regulators, mainly the MDM2 and MDMX proteins.
Thus, the design and synthesis of an inhibitor of the
MDM2–p53 interaction could enable p53 and reverse tumor
formation [26-28]. Based on our knowledge to antagonize the
oncogenic protein–protein interaction p53–MDM2 [23,29-40]
we designed macrocyclic inhibitors in continuation of our
previous work [13,23]. Herein, an indole-based macrocycle syn-
thesis is reported in a one-pot fashion based on Ugi macrocy-
clization with readily available α,ω-amino acids. Moreover, in
continuation of our efforts in the design and synthesis of
macrocycles targeting the p53–MDM2 interaction demon-
strating the potential of these indole-based macrocycles, a
subset of them was screened searching for MDM2 inhibitors.
Compared to our previous indole-based macrocycles 1
following a different strategy (employing a classical Ugi-4C as
the key reaction) [23], this one-pot Ugi macrocyclization
leading to macrocycles 2 offers speed (one-pot procedure with
one purification step), much better yields, no need of expensive
catalysts as in ring-closing metathesis (RCM) reaction and
higher complexity/diversity on the macrocyclic ring, e.g., inser-




Based on our previous studies [13], unprotected diamines 3
were reacted in one-step with cyclic anhydrides 4 at rt affording
the appropriate α,ω-amino acids 5 in excellent yields (see Sup-
porting Information File 1). Elongated diamines (n = 2–4, 6, 8
and 10) and cyclic anhydrides that bear a heteroatom in the
4-position as oxygen or sulfur (Y = O, S, Scheme 2) were em-
ployed in order to enhance the diversity of our macrocycles [4].
Thus, in a parallel way, we readily synthesized 12 different
amino acids which were subsequently subjected to the Ugi
macrocyclization.
After quite some optimization, we improved the Ugi-macrocy-
clization procedure compared to our previous findings utilizing
microwave irradiation (see Supporting Information File 1);
Firstly, the corresponding amino acid was irradiated with
indole-3-carboxaldehyde derivatives 6 using MeOH as solvent
(5 mL) at 120 °C for 1 h. Then, tert-butyl isocyanide was
added, diluted with more MeOH and irradiated again the
reaction mixture at 120 °C for an additional 1 h in a final
concentration of 0.1 M (Scheme 3). By this way, a rapid, one-
Beilstein J. Org. Chem. 2019, 15, 513–520.
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Scheme 3: Ugi macrocyclization in a one-pot fashion and synthesis of diverse indole-based macrocycles. The circle depicts the size number of the
macrocycle.
Beilstein J. Org. Chem. 2019, 15, 513–520.
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Figure 1: (A) Modeling of the macrocycle 2h (cyan sticks) and 2n (magenta sticks) into the MDM2 receptor (PDB ID: 1YCR); (B) 2D structure of 2h
with the substituents targeting the subpockets of MDM2; (C) Analysis of the synthesized macrocycles probing the subpockets of MDM2 and expan-
sion of the chemistry compared to previous studies [13].
pot access to macrocycles 2a–p was achieved otherwise very
difficult to synthesize in relatively good yields (29–60%).
16 different indole-based macrocycles were synthesized
with their size varying from 11–13, 15, 17 and 19 atoms
(Scheme 3).
Biological evaluation
Our previously introduced three-point pharmacophore model on
mimicking the hot triad (Phe19, Trp23 and Leu26, F19W23L26)
was the basis of the evaluation of the current derivatives as po-
tent inhibitors [33]. The indole moiety could be used not only to
constrain the two other substituents but also as an “anchor”
mimicking the Trp23. The bulky tert-butyl group would mimic
the Phe19 and the macrocyclic ring would fill the Leu26 sub-
pocket as shown by our docking studies (Figure 1A,B, Figure
S4 in Supporting Information File 1). Thus, extending our
previous work [13], the Leu26 subpocket was probed by
utilizing the different ring sizes and the different heteroatoms
(oxygen or sulfur) of our macrocyclic library. In addition, the
influence of the chlorine atom in the 6-position of the indole
ring (Figure 1C) was examined. Macrocycles 2a–j consist of an
oxygen linker whereas 2g–j bear also a chlorine atom in the
Beilstein J. Org. Chem. 2019, 15, 513–520.
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Table 1: Measurement of Ki and Kd of the selected macrocycles based on FP and 1H,15N HSQC NMR assays, respectively.a
Entry Name Structure Ki MDM2 [µM] Kd MDM2 [µM]
1 2h 2.3 12.1 ± 8.5
2 2i 5.5 4.8 ± 1.5
3 2n 316 17.2 ± 3.8
4 2g n.a. 8.9 ± 1.2
an.a. no activity against MDM2 protein. Ki and Kd values were calculated based on fluorescence polarization binding and 1H,15N HSQC NMR assay,
respectively.
6-position in the indole ring. Macrocycles 2k–p incorporate
both a sulfur linker and the chlorine on the indole ring
(Scheme 3).
In order to exclude false positive hits, two biorthogonal assays
were chosen; 1H,15N HSQC NMR and fluorescence polariza-
tion (FP, Table 1). FP assay was employed to determine the
inhibitory affinities (Ki) of the derivatives against MDM2
as previously described [36]. Besides 2h (Ki = 2.3 μΜ,
Kd = 12.1 μΜ), it was shown that 2i demonstrated a promising
activity with a Ki of 5.5 μΜ. Furthermore, 1H,15N HSQC
showed a Kd of 4.8 μΜ (Table 1, Figure 2). Moreover, macro-
cycles 2g and 2n demonstrated a Kd of 9 μΜ and 17 μΜ, re-
spectively (Table 1). With this preliminary analysis, it was
found that a ring size of 15–17 atoms and an oxygen as the
heteroatom linker improves the binding affinity. All the active
macrocycles have a 6-chloro-substituted indole core. It is well
established that at the bottom of the Try23 pocket a hydro-
phobic small subpocket exists which is formed by Phe86,
Ile103, Leu82 and Leu57. This pocket when filled with a
smaller hydrophobic substituent such as -Cl boosts the inhibitor
activity in accordance with literature [33].
Beilstein J. Org. Chem. 2019, 15, 513–520.
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Figure 2: (A) Overlay of 1 H,15N-HSQC spectra of the reference MDM2 (red) and the titration steps with the 2i inhibitor. MDM2/2i ratios 4:1 (orange),
4:2 (yellow), 4:3 (green), 1:1 (light blue), 1:2 (blue), 1:5 (purple). Examples of most perturbed residues are labeled on the spectrum. (B) Normalized
chemical shift perturbations (δo) of MDM2 residue (calculated according to Stoll et al. [41]). Residue with δo equal 0 are either despairing from MDM2
spectrum upon titration or cannot be identified. (C) Chemical shift perturbations plotted onto the structure of MDM2 (wheat); orange (despairing – indi-
cating stronger binding), light orange (>0.1 ppm), yellow (0.05–0.1 ppm). Residues which disappear upon titration experiment are labeled on the
Mdm2 surface.
Beilstein J. Org. Chem. 2019, 15, 513–520.
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Conclusion
We effectively synthesized p53-MDM2 antagonists based on an
artificial macrocyclic scaffold. 16 different derivatives were ob-
tained and screened. The aforementioned artificial macrocycles
combine the indole ring, a motif found in many bioactive mole-
cules with the drug-like properties of a non-peptide macrocycle.
We hypothesize that these chimeric derivatives of an indole and
a macrocycle will offer new potential on specific PPIs and other
postgenomic targets as it was demonstrated with the p53-
MDM2 interaction.
Supporting Information
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